Science
David Sinclair plans to test whole-body rejuvenation drugs in the XPrize competition
The longevity researcher will conduct human trials of an oral "reprogramming" drug as part of a $101 million competition. The approach aims to reverse cellular aging through epigenetic reprogramming, though significant scientific challenges remain.
Read full story at MIT Technology Review →V:0.2 · A:0.6 · D:0.4
Related
Science
Inside interoception: The hidden sense of how you feel inside
MIT Technology Review explores interoception, the body's ability to sense internal signals like heartbeat and breathing....
Science
Why "reprogramming" is the buzziest approach to reversing aging right now
Life Biosciences has begun dosing its first human volunteer with an experimental treatment that attempts to reverse agin...
Science
DiffusionGemma: 4x faster text generation
Google DeepMind has released DiffusionGemma, a 26B mixture-of-experts model that uses text diffusion to achieve up to 4x...